KRAS and neoplasm: The findings that cytokine expression is influenced by KRAS signaling and mutations in KRAS are tightly linked to tumor‐promoting inflammation suggest a molecular link between inflammation and tumorigenesis and a viable therapeutic option for KRAS targeting.